ACE2 and COVID-19: The ability of kasugamycin to ameliorate CHI3L1 induction of ACE2 and SPP while exerting antiviral and antifibrotic effects and augmenting type 1 immune responses suggests that it is a useful agent that can be used as a prophylactic or therapeutic in COVID-19.